<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400985</url>
  </required_header>
  <id_info>
    <org_study_id>SENSE-HF, V.1, Dec.8, 2004</org_study_id>
    <nct_id>NCT00400985</nct_id>
  </id_info>
  <brief_title>Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure</brief_title>
  <acronym>SENSE-HF</acronym>
  <official_title>Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SENSE-HF study is a prospective, observational, international multi-center study
      prospectively evaluating the sensitivity and positive predictive value of the OptiVol Fluid
      Trends data in predicting Heart Failure related hospitalizations and health care utilizations
      associated with signs and/or symptoms of pulmonary congestion, and to define OptiVol clinical
      guidelines for subject therapy management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SENSE-HF study prospectively evaluates the OptiVol feature in the prediction of Heart
      Failure related events associated with signs and symptoms of pulmonary congestion and in the
      subject HF therapy management.

      The OptiVol feature is based on the measurement of daily intrathoracic impedance values,
      measurements that can be used to track changes in the subject's thoracic fluid status over
      time. An Alert warns the patient whenever a programmable threshold has been reached.

      The study is divided into three phases.

      The first phase is double-blinded and designed to determine the sensitivity and positive
      predictive value of the OptiVol Fluid Trends data for the detection of Heart Failure related
      hospitalizations with signs and/or symptoms of pulmonary congestion.

      In the second phase of the study, the Alert is turned ON and the positive predictive value of
      the first OptiVol Patient Alert for the development of signs and/or symptoms of pulmonary
      congestion will be evaluated.

      The third phase of the study allows for remote subject therapy management using the OptiVol
      Patient Alert. The patient management strategy is then based on the experience gained in the
      second study phase Physician actions taken in the occurrence of a Patient Alert will be
      summarized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion.</measure>
    <time_frame>34 days post device implant to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Implantable Device diagnostics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.</intervention_name>
    <description>SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.</description>
    <arm_group_label>Implantable Device diagnostics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully implanted InSync Sentry device (&lt; 34 days post implant or pocket
             revision)in the pectoral region;

          -  At least one HF-related hospitalization that required administration of IV medication
             (inotropes, nitrates, diuretics) within the last 12 months

          -  The Subject has a market released, transvenous, high voltage Right Ventricular lead

          -  The Subject is able to detect a Patient Alert signal

        Exclusion Criteria:

          -  &lt;18 years of age (or under a minimum age required by local law)

          -  Moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

          -  Post heart transplant or awaiting heart transplantation

          -  Primary pulmonary hypertension

          -  Renal insufficiency requiring dialysis

        Amendment to the inclusion criteria (Jul 06):

          -  Inclusion of patients with Concerto/Virtuoso devices.

          -  At least one HF-related hospitalization that required administration of IV (or
             uptitration of the oral medication)(inotropes, nitrates, diuretics)within the last 12
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viviane Conraads, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA, Antwerpen, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Cowie, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton Hospital, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com/</url>
    <description>Public website</description>
  </link>
  <reference>
    <citation>Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, Lau CP. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005 Aug 9;112(6):841-8. Epub 2005 Aug 1.</citation>
    <PMID>16061743</PMID>
  </reference>
  <results_reference>
    <citation>Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, Cowie MR. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011 Sep;32(18):2266-73. doi: 10.1093/eurheartj/ehr050. Epub 2011 Feb 28.</citation>
    <PMID>21362703</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2018</results_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, Congestive</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Ambulatory Monitoring</keyword>
  <keyword>Intrathoracic Impedance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>501 patients from 41 medical clinics in 13 countries were enrolled between March 4, 2005 and September 9, 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>All study participants received the same treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="449"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>system modification</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Cronic Heart Failure (CHF) patients with a Cardiac Resynchronization Therapy device system</title>
          <description>Patients with New York Heart Association (NYHA) functional class II-III and severely reduced left ventricular ejection fraction and at least one Heart Failure (HF)-related hospitalisation that required an increase of medication (inotropes, nitrates, diuretics) within the last 12 months were eligible for inclusion. Subject enrolment occurred after successful device implantation (implantable cardioverter-defibrillator (ICD), or a combination of implantable cardiac resynchronization with ICD (CRT-D) and before 34 days post-implant (at time when OptiVol Fluid Trend Data become available).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Device therapy</title>
          <units>units</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CRT-D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion.</title>
        <time_frame>34 days post device implant to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients received the same treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Prediction by OptiVol of HF-related Hospitalizations With Signs and/or Symptoms of Pulmonary Congestion.</title>
          <units>hospitalization</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HF related hospitalization</sub_title>
                <counts group_id="E1" events="58" subjects_affected="42" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.9</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure decompensation</sub_title>
                <counts group_id="E1" events="104" subjects_affected="52" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director CRDM</name_or_title>
      <organization>Medtronic BRC, The Netherlands, Maastricht</organization>
      <phone>+31 43 3566 ext 566</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

